All News

NKx

FDA RMAT Designation Granted to Fate Therapeutics for FT516 Treatment of Relapsed/Refractory DLBCL
16 December 2021
FDA RMAT Designation Granted to Fate Therapeutics for FT516 Treatment of Relapsed/Refractory DLBCL
News
Strategic Manufacturing Partnership Announced Between Gates Biomanufacturing Facility and Nkarta
6 October 2021
Strategic Manufacturing Partnership Announced Between Gates Biomanufacturing Facility and Nkarta
News
Next-Generation CAR-T, Car-M and NK/NKT Platform Launched, Focussed on Curing Difficult-To-Treat Cancers
16 June 2021
Next-Generation CAR-T, Car-M and NK/NKT Platform Launched, Focussed on Curing Difficult-To-Treat Cancers
Inceptor Bio has announced the
Research Collaboration Seeks to Optimise Dual-Targeted NK Cell Therapy Against Acute Myeloid Leukaemia
26 May 2021
Research Collaboration Seeks to Optimise Dual-Targeted NK Cell Therapy Against Acute Myeloid Leukaemia
A new research agreement, funded
POPULAR NEWS ITEMS
Image
23 March 2023

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image
14 March 2023

Pfizer Invests $43 Billion to Acquire Seagen

Image
2 March 2023

Early Adoption and Partnerships – The Secret to Commercialization Success?

Enabling Next Generation Cell Therapies with GMP-Grade Human iPSCs
3 March 2021
Enabling Next Generation Cell Therapies with GMP-Grade Human iPSCs
Are induced pluripotent stem cells
Harnessing the Power of the Innate Immune System Using NK Cells
8 January 2019
Harnessing the Power of the Innate Immune System Using NK Cells
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers

Image

Pfizer Invests $43 Billion to Acquire Seagen

Image

Early Adoption and Partnerships – The Secret to Commercialization Success?